# National Healthcare Corp: overview

NHC · NYSE · CIK 1047335 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nhc.md) · [Financials](/companies/nhc/financials.md) · [Filings](/companies/nhc/filings.md) · [Insiders](/companies/nhc/insiders.md)

Latest reported revenue: [$408.0m](/filings/0001437749-26-026199.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-026199).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [340](/filings/0001437749-25-033631.md) | [369 d](/filings/0001437749-26-005910.md) | [374](/filings/0001437749-26-015612.md) | [375](/filings/0001437749-26-026199.md) | [383](/filings/0001437749-25-033631.md) | [387 d](/filings/0001437749-26-005910.md) | [382](/filings/0001437749-26-015612.md) | [408](/filings/0001437749-26-026199.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [6.7%](/filings/0001437749-25-033631.md) | [7.8% d](/filings/0001437749-26-005910.md) | [8.2%](/filings/0001437749-26-015612.md) | [9.1%](/filings/0001437749-26-026199.md) | [7.9%](/filings/0001437749-25-033631.md) | [8.6% d](/filings/0001437749-26-005910.md) | [8.4%](/filings/0001437749-26-015612.md) | [12.0%](/filings/0001437749-26-026199.md) |
| Net margin | % | [12.6%](/filings/0001437749-25-033631.md) | [1.6% d](/filings/0001437749-26-005910.md) | [8.6%](/filings/0001437749-26-015612.md) | [6.3%](/filings/0001437749-26-026199.md) | [10.3%](/filings/0001437749-25-033631.md) | [6.4% d](/filings/0001437749-26-005910.md) | [9.4%](/filings/0001437749-26-015612.md) | [9.9%](/filings/0001437749-26-026199.md) |
| Diluted EPS | $ per share | [2.73](/filings/0001437749-25-033631.md) | not reported | [2.07](/filings/0001437749-26-015612.md) | [1.52](/filings/0001437749-26-026199.md) | [2.50](/filings/0001437749-25-033631.md) | not reported | [2.27](/filings/0001437749-26-015612.md) | [2.54](/filings/0001437749-26-026199.md) |
| Free cash flow | $m | [28.6 d](/filings/0001437749-25-033631.md) | [4.6 d](/filings/0001437749-26-005910.md) | [33.1](/filings/0001437749-26-015612.md) | [52.6 d](/filings/0001437749-26-026199.md) | [56.5 d](/filings/0001437749-25-033631.md) | [6.4 d](/filings/0001437749-26-005910.md) | [52.9](/filings/0001437749-26-015612.md) | [30.7 d](/filings/0001437749-26-026199.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,074](/filings/0001437749-24-004619.md) | [1,086](/filings/0001437749-25-005928.md) | [1,142](/filings/0001437749-26-005910.md) | [1,307](/filings/0001437749-26-005910.md) | [1,518](/filings/0001437749-26-005910.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.7%](/filings/0001437749-24-004619.md) | [2.9%](/filings/0001437749-25-005928.md) | [5.0%](/filings/0001437749-26-005910.md) | [6.9%](/filings/0001437749-26-005910.md) | [8.5%](/filings/0001437749-26-005910.md) |
| Net margin | % | [12.9%](/filings/0001437749-24-004619.md) | [2.1%](/filings/0001437749-25-005928.md) | [5.9%](/filings/0001437749-26-005910.md) | [7.8%](/filings/0001437749-26-005910.md) | [7.9%](/filings/0001437749-26-005910.md) |
| Diluted EPS | $ per share | [8.99](/filings/0001437749-24-004619.md) | [1.45](/filings/0001437749-25-005928.md) | [4.34](/filings/0001437749-26-005910.md) | [6.53](/filings/0001437749-26-005910.md) | [7.67](/filings/0001437749-26-005910.md) |
| Free cash flow | $m | [23.0](/filings/0001437749-24-004619.md) | [(21.5)](/filings/0001437749-25-005928.md) | [83.3](/filings/0001437749-26-005910.md) | [79.7](/filings/0001437749-26-005910.md) | [149](/filings/0001437749-26-005910.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nhc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $417.6m | 1,975,785 |  | Added +80,535 |
| [Morgan Stanley Institutional Investment Advisors LLC](/funds/2026079.md) | 2026-06-30 | $217.4m | 1,028,534 |  | Reduced −10,270 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $196.5m | 929,692 |  | Reduced −17,285 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $171.0m | 809,224 |  | Added +19,803 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $154.4m | 730,573 |  | Added +200,271 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $116.7m | 552,136 |  | Added +2,588 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $111.7m | 526,732 |  | Added +35,157 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $80.5m | 380,934 |  | Added +57,667 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $63.3m | 299,717 |  | Reduced −35,800 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $37.0m | 175,290 |  | Added +25,094 |

## Recent filings

[All 1,279 filings](/companies/nhc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-11 | 14:39 ET | [8-K](/filings/0001437749-26-026960.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-026960 |
| 2026-08-11 | 14:38 ET | [8-K](/filings/0001437749-26-026957.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026957 |
| 2026-08-06 | 14:53 ET | [10-Q](/filings/0001437749-26-026199.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026199 |
| 2026-07-01 | 16:43 ET | [8-K](/filings/0001437749-26-022306.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-022306 |
| 2026-05-27 | 17:13 ET | [8-K](/filings/0001437749-26-018604.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-26-018604 |
| 2026-05-15 | 16:04 ET | [8-K](/filings/0001437749-26-017374.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-017374 |
| 2026-05-13 | 09:57 ET | [8-K](/filings/0001437749-26-016571.md) | 5.07 Shareholder vote results | 0001437749-26-016571 |
| 2026-05-08 | 11:28 ET | [8-K](/filings/0001437749-26-015802.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015802 |
| 2026-05-07 | 16:28 ET | [10-Q](/filings/0001437749-26-015612.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015612 |
| 2026-05-07 | 16:23 ET | [8-K](/filings/0001437749-26-015606.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-015606 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-005910.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7771f971-58f5-4f06-ae2b-2d2824d4cfbd)

## About the filer

- CIK: 1047335
- Tickers: NHC
- Exchange: NYSE
- SIC code: 8051 Services-Skilled Nursing Care Facilities
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 10:11 ET. No prices; not investment advice.